From the American Academy of Ophthalmology

Researchers report the three-year results of a predominantly visual acuity-driven ranibizumab re-treatment regimen in 160 consecutive patients with wet AMD. Patients were treated with three initial injections followed by as-needed dosing for the first year at an academic referral center. After stabilization, they were followed for two years in private practices in collaboration with the referral center and re-treated based on visual acuity loss. Despite an initial stabilization of function and morphology, the therapeutic benefit was lost during long-term follow-up and irreversible degenerative changes occurred. Retina, September 2012